These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 21158979)

  • 21. Dendritic cells in the tumor microenvironment: prognostic and theranostic impact.
    Verneau J; Sautés-Fridman C; Sun CM
    Semin Immunol; 2020 Apr; 48():101410. PubMed ID: 33011065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    Rolinski J; Hus I
    J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of dendritic cell therapy for cancer: progress and challenges.
    Mantia-Smaldone GM; Chu CS
    BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands.
    Raaijmakers TK; Ansems M
    Cancer Immunol Immunother; 2018 Nov; 67(11):1789-1796. PubMed ID: 29998375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
    Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
    Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference.
    Sioud M
    Methods Mol Biol; 2020; 2115():259-280. PubMed ID: 32006406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic/tumor fusion cell-based vaccination against cancer.
    Koido S; Hara E; Homma S; Fujise K; Gong J; Tajiri H
    Arch Immunol Ther Exp (Warsz); 2007; 55(5):281-7. PubMed ID: 18219758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic-cell-based therapeutic cancer vaccines.
    Palucka K; Banchereau J
    Immunity; 2013 Jul; 39(1):38-48. PubMed ID: 23890062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing dendritic cells in cancer.
    Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
    Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
    Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
    J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of tumour-responsive T cells as cancer treatment.
    Disis ML; Bernhard H; Jaffee EM
    Lancet; 2009 Feb; 373(9664):673-83. PubMed ID: 19231634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
    Huber A; Dammeijer F; Aerts JGJV; Vroman H
    Front Immunol; 2018; 9():2804. PubMed ID: 30559743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
    Saxena M; Bhardwaj N
    Trends Cancer; 2018 Feb; 4(2):119-137. PubMed ID: 29458962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
    Pyzer AR; Avigan DE; Rosenblatt J
    Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.
    Homma S; Sagawa Y; Ito M; Ohno T; Toda G
    Clin Exp Immunol; 2006 Apr; 144(1):41-7. PubMed ID: 16542363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
    Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
    Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.